The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
Open accessAbstract
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citation
Research works printed but not linked: 5
- Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962–2972. · DOI · Paper page
- Madan S, Kumar S . Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol 2009; 7: 802–804.
- Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2009; 21: 325–330. · DOI · Paper page
- Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas [see comment]. Br J Haematol 2001; 113: 422–424. · DOI
- Rosiñol L, Cibeira M, Bladé J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836.
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationMikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Self-citationMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Self-citationExtramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
“[30] studied the detailed medical records of 174 consecutive patients with RRMM who enrolled in a phase 2 clinical trial of pomalidomide plus low-dose dexamethasone.”
BackgroundRajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
“The most common reciprocal translocations in the IgH translocated subgroup of MM are t(11;14), t(4;14), t(14;16), t(14;20) and t(6;14).”
BackgroundSelf-citationRosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17338 · Cited by 179
Self-citationMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Self-citationThe application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Extramedullary disease in plasma cell myeloma: the iceberg phenomenon
Wirk, B., Wingard, J. R., & Moreb, J. S. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.26 · Cited by 49
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
Metadata
- Authors
- Short, K. D., Rajkumar, S. V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V, Kyle, R. A., & Lacy, M. Q.
- Venue
- Leukemia
- Published
- 2011-02-25
- Volume
- 25
- Issue
- 6
- Pages
- 906-908
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2057660602
- Cited by
- 209
- References
- 1
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.